LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,093
تعداد مقالات10,023
تعداد مشاهده مقاله27,225,744
تعداد دریافت فایل اصل مقاله7,475,070
Suhail Najm Alareer, Hayder, Arian, Arvin, Fotouhi, Maryam, Taher, Hayder Jasim, Dinar Abdullah, Ayoob. (1402). Evidence Supporting Diagnostic Value of Liver Imaging Reporting and Data System for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. سامانه مدیریت نشریات علمی, 14(1), 5-20. doi: 10.31661/jbpe.v0i0.2211-1562
Hayder Suhail Najm Alareer; Arvin Arian; Maryam Fotouhi; Hayder Jasim Taher; Ayoob Dinar Abdullah. "Evidence Supporting Diagnostic Value of Liver Imaging Reporting and Data System for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis". سامانه مدیریت نشریات علمی, 14, 1, 1402, 5-20. doi: 10.31661/jbpe.v0i0.2211-1562
Suhail Najm Alareer, Hayder, Arian, Arvin, Fotouhi, Maryam, Taher, Hayder Jasim, Dinar Abdullah, Ayoob. (1402). 'Evidence Supporting Diagnostic Value of Liver Imaging Reporting and Data System for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis', سامانه مدیریت نشریات علمی, 14(1), pp. 5-20. doi: 10.31661/jbpe.v0i0.2211-1562
Suhail Najm Alareer, Hayder, Arian, Arvin, Fotouhi, Maryam, Taher, Hayder Jasim, Dinar Abdullah, Ayoob. Evidence Supporting Diagnostic Value of Liver Imaging Reporting and Data System for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. سامانه مدیریت نشریات علمی, 1402; 14(1): 5-20. doi: 10.31661/jbpe.v0i0.2211-1562

Evidence Supporting Diagnostic Value of Liver Imaging Reporting and Data System for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Journal of Biomedical Physics and Engineering
دوره 14، شماره 1، اردیبهشت 2024، صفحه 5-20    اصل مقاله (2.32 M)
نوع مقاله: Systematic Review
شناسه دیجیتال (DOI): 10.31661/jbpe.v0i0.2211-1562
نویسندگان
Hayder Suhail Najm Alareer1؛ Arvin Arian* 2؛ Maryam Fotouhi3؛ Hayder Jasim Taher4؛ Ayoob Dinar Abdullah5
1Department of Radiology, College of Health and Medical Technology, Al-Ayen University, Thi-Qar, 64001, Iraq
2Cancer Institute ADIR, Tehran University of Medical Sciences (TUMS), Tehran, Iran
3Quantitative MR Imaging and Spectroscopy Group (QMISG), Research Centre for Molecular and Cellular Imaging (RCMCI), Advanced Medical Technologies and Equipment Institute (AMTEI), Tehran University of Medical Sciences (TUMS), Tehran, Iran
4Department of Radiology, Hilla University College, Babylon, Iraq
5Department of Radiology Technology, Al-Manara College for Medical Sciences, Missan, Iraq
چکیده
Background: Based on the Liver Imaging Data and Reporting System (LI-RADS) guidelines, Hepatocellular Carcinoma (HCC) can be diagnosed using imaging criteria in patients at risk of HCC.
Objective: This study aimed to assess the diagnostic value of LI-RADS in high-risk patients with HCC.
Material and Methods: This systematic review is conducted on international databases, including Google Scholar, Web of Science, PubMed, Embase, PROQUEST, and Cochrane Library, with appropriate keywords. Using the binomial distribution formula, the variance of each study was calculated, and all the data were analyzed using STATA version 16. The pooled sensitivity and specificity were determined using a random-effects meta-analysis approach. Also, we used the chi-squared test and I2 index to calculate heterogeneity among studies, and Funnel plots and Egger tests were used for evaluating publication bias.
Results: The pooled sensitivity was estimated at 0.80 (95% CI: 0.76-0.84). According to different types of Liver Imaging Reporting and Data Systems (LI-RADS), the highest pooled sensitivity was in version 2018 (0.83 (95% CI: 0.79-0.87) (I2: 80.6%, P of chi 2 test for heterogeneity: <0.001 and T2: 0.001). The pooled specificity was estimated as 0.89 (95% CI: 0.87-0.92). According to different types of LI-RADS, the highest pooled specificity was in version 2014 (93.0 (95% CI: 89.0-96.0) (I2: 81.7%, P of chi 2 test for heterogeneity: <0.001 and T2: 0.001).  
Conclusion: LI-RADS can assist radiologists in achieving the required sensitivity and specificity in high-risk patients suspected to have HCC. Therefore, this strategy can serve as an appropriate tool for identifying HCC.
کلیدواژه‌ها
Carcinoma؛ Hepatocellular؛ Magnetic Resonance Imaging؛ CT؛ LI-RADS
سایر فایل های مرتبط با مقاله
مراجع
  1. Kudo M. Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer. 2015;4(1):39-50. doi: 10.1159/000367727. PubMed PMID: 26020028. PubMed PMCID: PMC4439792.
  2. Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. 2016;150(4):835-53. doi: 10.1053/j.gastro.2015.12.041. PubMed PMID: 26795574.
  3. Puoti C. New insights on hepatocellular carcinoma: epidemiology and clinical aspects. Hepatoma Res. 2018;4:57.
  4. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108. doi: 10.3322/caac.21262. PubMed PMID: 25651787.
  5. Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, García-Criado Á, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol. 2018;101:72-81. doi: 10.1016/j.ejrad.2018.01.025. PubMed PMID: 29571804.
  6. Elsayes KM, Hooker JC, Agrons MM, Kielar AZ, Tang A, Fowler KJ, et al. 2017 Version of LI-RADS for CT and MR Imaging: An Update. Radiographics. 2017;37(7):1994-2017. doi: 10.1148/rg.2017170098. PubMed PMID: 29131761.
  7. Poulou LS, Botsa E, Thanou I, Ziakas PD, Thanos L. Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Hepatol. 2015;7(8):1054-63. doi: 10.4254/wjh.v7.i8.1054. PubMed PMID: 26052394. PubMed PMCID: PMC4450182.
  8. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. 2014;272(3):635-54. doi: 10.1148/radiol.14132361. PubMed PMID: 25153274. PubMed PMCID: PMC4263631.
  9. Tang A, Valasek MA, Sirlin CB. Update on the Liver Imaging Reporting and Data System: What the Pathologist Needs to Know. Adv Anat Pathol. 2015;22(5):314-22. doi: 10.1097/PAP.0000000000000089. PubMed PMID: 26262514.
  10. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529-36. doi: 10.7326/0003-4819-155-8-201110180-00009. PubMed PMID: 22007046.
  11. Ren AH, Zhao PF, Yang DW, Du JB, Wang ZC, Yang ZH. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017. J Magn Reson Imaging. 2019;50(3):746-55. doi: 10.1002/jmri.26640. PubMed PMID: 30648327.
  12. Cha DI, Choi GS, Kim YK, Kim JM, Kang TW, Song KD, Ahn SH. Extracellular contrast-enhanced MRI with diffusion-weighted imaging for HCC diagnosis: prospective comparison with gadoxetic acid using LI-RADS. Eur Radiol. 2020;30(7):3723-34. doi: 10.1007/s00330-020-06753-5. PubMed PMID: 32128620.
  13. Ludwig DR, Fraum TJ, Cannella R, Tsai R, Naeem M, LeBlanc M, et al. Expanding the Liver Imaging Reporting and Data System (LI-RADS) v2018 diagnostic population: performance and reliability of LI-RADS for distinguishing hepatocellular carcinoma (HCC) from non-HCC primary liver carcinoma in patients who do not meet strict LI-RADS high-risk criteria. HPB (Oxford). 2019;21(12):1697-706. doi: 10.1016/j.hpb.2019.04.007. PubMed PMID: 31262487.
  14. Chaudhry M, McGinty KA, Mervak B, Lerebours R, Li C, Shropshire E, et al. The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma. Radiology. 2020;294(2):320-6. doi: 10.1148/radiol.2019191581. PubMed PMID: 31845843.
  15. Kierans AS, Song C, Gavlin A, Roudenko A, Lu L, Askin G, Hecht EM. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma. Am J Roentgenol. 2020;215(5):1085-92. doi: 10.2214/AJR.20.22772. PubMed PMID: 32877248.
  16. De Gaetano AM, Catalano M, Pompili M, Marini MG, Rodríguez Carnero P, et al. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging. Eur Rev Med Pharmacol Sci. 2019;23(18):7786-801. doi: 10.26355/eurrev_201909_18988. PubMed PMID: 31599447.
  17. Chan A, Sertic M, Sammon J, Kim TK, Jang HJ, Guimaraes L, et al. Diagnostic imaging of hepatocellular carcinoma at community hospitals and their tertiary referral center in the era of LI-RADS: a quality assessment study. Abdom Radiol (NY). 2019;44(12):4028-36. doi: 10.1007/s00261-019-02237-3. PubMed PMID: 31555846.
  18. Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, et al. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology. 2018;289(3):816-30. doi: 10.1148/radiol.2018181494. PubMed PMID: 30251931. PubMed PMCID: PMC6677371.
  19. Lee S, Kim MJ, Kim SS, Shin H, Kim DY, Choi JY, Park MS, Mitchell DG. Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Hepatol Int. 2020;14(1):70-9. doi: 10.1007/s12072-019-10002-3. PubMed PMID: 31802388.
  20. Jiang H, Liu X, Chen J, Wei Y, Lee JM, Cao L, et al. Man or machine? Prospective comparison of the version 2018 EASL, LI-RADS criteria and a radiomics model to diagnose hepatocellular carcinoma. Cancer Imaging. 2019;19(1):1-13. doi: 10.1186/s40644-019-0266-9. PubMed PMID: 31806050. PubMed PMCID: PMC6896342.
  21. Khatri G, Pedrosa I, Ananthakrishnan L, De Leon AD, Fetzer DT, Leyendecker J, et al. Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LI-RADS v2018. J Magn Reson Imaging. 2020;51(2):415-25. doi: 10.1002/jmri.26835. PubMed PMID: 31209978.
  22. Kim YY, Kim MJ, Kim EH, Roh YH, An C. Hepatocellular Carcinoma versus Other Hepatic Malignancy in Cirrhosis: Performance of LI-RADS Version 2018. 2019;291(1):72-80. doi: 10.1148/radiol.2019181995. PubMed PMID: 30694166.
  23. Vernuccio F, Cannella R, Meyer M, Choudhoury KR, Gonzáles F, Schwartz FR, et al. LI-RADS: Diagnostic Performance of Hepatobiliary Phase Hypointensity and Major Imaging Features of LR-3 and LR-4 Lesions Measuring 10-19 mm With Arterial Phase Hyperenhancement. Am J Roentgenol. 2019;213(2):W57-65. doi: 10.2214/AJR.18.20979. PubMed PMID: 31039012.
  24. Yoon JH, Lee JM, Lee YJ, Lee KB, Han JK. Added Value of sequentially performed gadoxetic acid-enhanced liver MRI for the diagnosis of small (10-19 mm) or atypical hepatic observations at contrast-enhanced CT: A prospective comparison. J Magn Reson Imaging. 2019;49(2):574-87. doi: 10.1002/jmri.26199. PubMed PMID: 30102433.
  25. Smereka P, Doshi AM, Lavelle LP, Shanbhogue K. New Arterial Phase Enhancing Nodules on MRI of Cirrhotic Liver: Risk of Progression to Hepatocellular Carcinoma and Implications for LI-RADS Classification. Am J Roentgenol. 2020;215(2):382-9. doi: 10.2214/AJR.19.22033. PubMed PMID: 32432909.
  26. Rosiak G, Podgorska J, Rosiak E, Cieszanowski A. Comparison of LI-RADS v.2017 and ESGAR Guidelines Imaging Criteria in HCC Diagnosis Using MRI with Hepatobiliary Contrast Agents. Biomed Res Int. 2018;2018:7465126. doi: 10.1155/2018/7465126. PubMed PMID: 30105242. PubMed PMCID: PMC6076943.
  27. Basha MAA, Refaat R, Mohammad FF, Khamis MEM, El-Maghraby AM, El Sammak AA, et al. The utility of diffusion-weighted imaging in improving the sensitivity of LI-RADS classification of small hepatic observations suspected of malignancy. Abdom Radiol (NY). 2019;44(5):1773-84. doi: 10.1007/s00261-018-01887-z. PubMed PMID: 30603882.
  28. Ding Y, Rao SX, Wang WT, Chen CZ, Li RC, Zeng M. Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017). Cancer Imaging. 2018;18(1):48. doi: 10.1186/s40644-018-0183-3. PubMed PMID: 30526674. PubMed PMCID: PMC6286579.
  29. Kim Y, Furlan A, Borhani AA, Bae KT. Computer-aided diagnosis program for classifying the risk of hepatocellular carcinoma on MR images following liver imaging reporting and data system (LI-RADS). J Magn Reson Imaging. 2018;47(3):710-22. doi: 10.1002/jmri.25772. PubMed PMID: 28556283.
  30. Liu W, Qin J, Guo R, Xie S, Jiang H, Wang X, Kang Z, Wang J, Shan H. Accuracy of the diagnostic evaluation of hepatocellular carcinoma with LI-RADS. Acta Radiol. 2018;59(2):140-6. doi: 10.1177/0284185117716700. PubMed PMID: 28648125.
  31. Zhang T, Huang ZX, Wei Y, Jiang HY, Chen J, Liu XJ, et al. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy? World J Gastroenterol. 2019;25(5):622-31. doi: 10.3748/wjg.v25.i5.622. PubMed PMID: 30774276. PubMed PMCID: PMC6371008.
  32. Song JS, Choi EJ, Hwang SB, Hwang HP, Choi H. LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI. Eur Radiol. 2019;29(1):401-10. doi: 10.1007/s00330-018-5559-z. PubMed PMID: 29922928.
  33. Fraum TJ, Tsai R, Rohe E, Ludwig DR, Salter A, Nalbantoglu I, Heiken JP, Fowler KJ. Differentiation of Hepatocellular Carcinoma from Other Hepatic Malignancies in Patients at Risk: Diagnostic Performance of the Liver Imaging Reporting and Data System Version 2014. Radiology. 2018;286(1):158-72. doi: 10.1148/radiol.2017170114. PubMed PMID: 28853673.
  34. Bae JS, Kim JH, Yu MH, Lee DH, Kim HC, Chung JW, Han JK. Diagnostic accuracy of gadoxetic acid-enhanced MR for small hypervascular hepatocellular carcinoma and the concordance rate of Liver Imaging Reporting and Data System (LI-RADS). PLoS One. 2017;12(5):e0178495. doi: 10.1371/journal.pone.0178495. PubMed PMID: 28558068. PubMed PMCID: PMC5448778.
  35. Becker AS, Barth BK, Marquez PH, Donati OF, Ulbrich EJ, Karlo C, et al. Increased interreader agreement in diagnosis of hepatocellular carcinoma using an adapted LI-RADS algorithm. Eur J Radiol. 2017;86:33-40. doi: 10.1016/j.ejrad.2016.11.004. PubMed PMID: 28027763.
  36. Cerny M, Chernyak V, Olivié D, Billiard JS, Murphy-Lavallée J, et al. LI-RADS Version 2018 Ancillary Features at MRI. 2018;38(7):1973-2001. doi: 10.1148/rg.2018180052. PubMed PMID: 30289735.
  37. Chen N, Motosugi U, Morisaka H, Ichikawa S, Sano K, Ichikawa T, et al. Added Value of a Gadoxetic Acid-enhanced Hepatocyte-phase Image to the LI-RADS System for Diagnosing Hepatocellular Carcinoma. Magn Reson Med Sci. 2016;15(1):49-59. doi: 10.2463/mrms.2014-0149. PubMed PMID: 26104079.
  38. Furlan A, Almusa O, Yu RK, Sagreiya H, Borhani AA, Bae KT, Marsh JW. A radiogenomic analysis of hepatocellular carcinoma: association between fractional allelic imbalance rate index and the liver imaging reporting and data system (LI-RADS) categories and features. Br J Radiol. 2018;91(1086):20170962. doi: 10.1259/bjr.20170962. PubMed PMID: 29565672. PubMed PMCID: PMC6223296.
  39. Hicks RM, Yee J, Ohliger MA, Weinstein S, Kao J, Ikram NS, Hope TA. Comparison of diffusion-weighted imaging and T2-weighted single shot fast spin-echo: Implications for LI-RADS characterization of hepatocellular carcinoma. Magn Reson Imaging. 2016;34(7):915-21. doi: 10.1016/j.mri.2016.04.007. PubMed PMID: 27108359. PMCID: PMC5325126.
  40. Horvat N, Nikolovski I, Long N, Gerst S, Zheng J, Pak LM, et al. Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014. Abdom Radiol (NY). 2018;43(1):169-78. doi: 10.1007/s00261-017-1261-x. PubMed PMID: 28765978. PubMed PMCID: PMC6598685.
  41. Joo I, Lee JM, Lee SM, Lee JS, Park JY, Han JK. Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI. J Magn Reson Imaging. 2016;44(5):1330-8. doi: 10.1002/jmri.25287. PubMed PMID: 27087012.
  42. Ronot M, Fouque O, Esvan M, Lebigot J, Aubé C, Vilgrain V. Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3 cm. J Hepatol. 2018;68(4):715-23. doi: 10.1016/j.jhep.2017.12.014. PubMed PMID: 29274407.
  43. Tang Q, Ma C. Performance of Gd-EOB-DTPA-enhanced MRI for the diagnosis of LI-RADS 4 category hepatocellular carcinoma nodules with different diameters. Oncol Lett. 2018;16(2):2725-31. doi: 10.3892/ol.2018.8884. PubMed PMID: 30008946. PubMed PMCID: PMC6036548.
  44. Mayerhoefer ME, Schima W, Trattnig S, Pinker K, Berger-Kulemann V, Ba-Ssalamah A. Texture-based classification of focal liver lesions on MRI at 3.0 Tesla: a feasibility study in cysts and hemangiomas. J Magn Reson Imaging. 2010;32(2):352-9. doi: 10.1002/jmri.22268. PubMed PMID: 20677262.
  45. Lee SM, Lee JM, Ahn SJ, Kang HJ, Yang HK, Yoon JH. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI. Radiology. 2019;292(3):655-63. doi: 10.1148/radiol.2019182867. PubMed PMID: 31310175.
  46. Lee S, Kim SS, Roh YH, Choi JY, Park MS, Kim MJ. Diagnostic Performance of CT/MRI Liver Imaging Reporting and Data System v2017 for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Liver Int. 2020;40(6):1488-97. doi: 10.1111/liv.14424. PubMed PMID: 32145134.
  47. Van Der Pol CB, Lim CS, Sirlin CB, McGrath TA, Salameh JP, Bashir MR, et al. Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy-A Systematic Review. Gastroenterology. 2019;156(4):976-86. doi: 10.1053/j.gastro.2018.11.020. PubMed PMID: 30445016.
  48. Kim DH, Choi SH, Park SH, Kim KW, Byun JH, Kim SY, et al. Meta-analysis of the accuracy of Liver Imaging Reporting and Data System category 4 or 5 for diagnosing hepatocellular carcinoma. Gut. 2019;68(9):1719-21. doi: 10.1136/gutjnl-2019-318555. PubMed PMID: 31300516.
  49. Moura Cunha G, Chernyak V, Fowler KJ, Sirlin CB. Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021;8:513-27. doi: 10.2147/JHC.S268288. PubMed PMID: 34104640. PubMed PMCID: PMC8180267.
  50. Di Martino M, Marin D, Guerrisi A, Baski M, Galati F, Rossi M, et al. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. Radiology. 2010;256(3):806-16. doi: 10.1148/radiol.10091334. PubMed PMID: 20720069.
  51. Hanna RF, Miloushev VZ, Tang A, Finklestone LA, Brejt SZ, Sandhu RS, et al. Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol (NY). 2016;41(1):71-90. doi: 10.1007/s00261-015-0592-8. PubMed PMID: 26830614.
  52. Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology. 2018;154(6):1706-18. doi: 10.1053/j.gastro.2018.01.064. PubMed PMID: 29425931. PubMed PMCID: PMC5927818.
  53. Kim SY, An J, Lim YS, Han S, Lee JY, Byun JH, et al. MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma. JAMA Oncol. 2017;3(4):456-63. doi: 10.1001/jamaoncol.2016.3147. PubMed PMID: 27657493. PubMed PMCID: PMC5470420.
  54. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723-50. doi: 10.1002/hep.29913. PubMed PMID: 29624699.
  55. Chou R, Cuevas C, Fu R, Devine B, Wasson N, Ginsburg A, et al. Imaging Techniques for the Diagnosis of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;162(10):697-711. doi: 10.7326/M14-2509. PubMed PMID: 25984845.
  56. Son JH, Choi SH, Kim SY, Jang HY, Byun JH, Won HJ, et al. Validation of US Liver Imaging Reporting and Data System Version 2017 in Patients at High Risk for Hepatocellular Carcinoma. 2019;292(2):390-7. doi: 10.1148/radiol.2019190035. PubMed PMID: 31210614.
آمار
تعداد مشاهده مقاله: 102,798
تعداد دریافت فایل اصل مقاله: 312


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب